抗TNF治疗炎症性肠病25年:经验与展望
抗TNF抗体用于炎症性肠病约25年。首例难治性克罗恩病患者对英夫利昔单抗快速应答促进加速研发和批准,但维持方案、药代动力学、毒性和定位等问题当时未解。作者回顾抗TNF历程,总结经验教训,为未来更强更安全疗法提供平台。
要点
- 抗TNF治疗已应用约25年,英夫利昔单抗首例难治性克罗恩病快速应答推动加速批准。
- 过去25年经验为开发更强更安全疗法奠定平台,强调不应忘记从过去学习。
核心结论
- 抗TNF治疗约25年的经验教训为未来开发更强更安全疗法创建了平台,应继续从过去学习。
研究设计与样本
- 综述类:作者基于自身最早在克罗恩病使用英夫利昔单抗的经验,回顾抗TNF治疗25年临床使用历程。
主要发现
- 首例难治性克罗恩病患者对英夫利昔单抗快速应答,促使该适应症加速临床开发和批准。
- 即使至今,抗TNF治疗仍在出现新见解。
临床怎么用
- 临床使用抗TNF时应重视过去25年积累的维持方案、药代动力学、毒性和定位经验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Anti-tumour necrosis factor (TNF) antibodies have been widely used for approximately 25 years now. The first clinical observations in patients with refractory Crohn's disease rapidly responding to infliximab prompted accelerated clinical development and approval for this indication. However, many questions remained unanswered when this treatment came to market related to maintenance schedules, pharmacokinetics, toxicity and positioning. Many of these open questions were addressed by investigators and sponsors during more than two decades of clinical use. The authors were among the first to use infliximab in Crohn's disease and felt that now is a good time to look back and draw lessons from the remarkable anti-TNF story. Even today, new insights continue to appear. But more importantly, what was learnt in the past 25 years has created a platform for future development of even stronger and safer therapies. We should not forget to learn from the past.
引用
- D'Haens GR, van Deventer S. 25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the future. Gut. 2021. PMID: 33431575. doi:10.1136/gutjnl-2019-320022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。